MARKET

FATE

FATE

Fate Therapeutic
NASDAQ
5.47
-0.05
-0.91%
Closed 18:30 06/07 EDT
OPEN
5.53
PREV CLOSE
5.52
HIGH
5.60
LOW
5.35
VOLUME
1.88M
TURNOVER
--
52 WEEK HIGH
37.13
52 WEEK LOW
4.020
MARKET CAP
538.16M
P/E (TTM)
-2.2598
1D
5D
1M
3M
1Y
5Y
Fate Therapeutic: Statement of changes in beneficial ownership of securities
Press release · 1d ago
Fate Therapeutic: Current report
Press release · 1d ago
Fate Therapeutics (FATE) Down 17.8% Since Last Earnings Report: Can It Rebound?
NASDAQ · 6d ago
Fate Therapeutics: The Future Remains Cloudy
Seeking Alpha · 05/23 17:40
HC Wainwright & Co. Reiterates Fate Therapeutics (FATE) Neutral Recommendation
NASDAQ · 05/06 10:26
SVB Securities Sticks to Its Buy Rating for Fate Therapeutics (FATE)
TipRanks · 05/05 15:16
Where Fate Therapeutics Stands With Analysts
Benzinga · 05/05 15:02
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neurocrine (NBIX), Fate Therapeutics (FATE) and Envista Holdings (NVST)
TipRanks · 05/05 11:30
More
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of programmed cellular immunotherapies for patients with cancer and autoimmune disorders. It uses human induced pluripotent stem cells (iPSCs) generated from its iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The Company is advancing a pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted natural killer (NK) and T-cell product candidates. The Company's product pipeline includes FT576, FT819, FT825 and FT522. Its FT576, is an iPSC-derived, B-cell maturation antigen (BCMA)-targeted CAR NK cell product candidate for the treatment of multiple myeloma. Its FT819, is an iPSC-derived CAR T-cell therapy candidate, which is in Phase I study for the treatment of adult patients with relapsed / refractory B-cell malignancies, including B-cell lymphoma and chronic lymphocytic leukemia.

Webull offers kinds of Fate Therapeutics Inc stock information, including NASDAQ:FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.